<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531724</url>
  </required_header>
  <id_info>
    <org_study_id>SahlgrenskaUHThoraxLL3</org_study_id>
    <nct_id>NCT02531724</nct_id>
  </id_info>
  <brief_title>Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery</brief_title>
  <acronym>LEVOAKI</acronym>
  <official_title>Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a common complication after cardiac surgery. Mismatch in renal
      oxygen demand-supply may be an important pathogenetic factor. Levosimendan has been shown to
      improve renal blood flow, glomerular filtration rate and renal oxygenation in healthy
      controls after cardiac surgery.

      In order to investigate the effect of levosimendan in patients with AKI after cardiac
      surgery, the investigators plan a randomized placebo controlled trial. 30 patients will
      receive levosimendan or placebo. Renal blood flow and filtration fraction will be measured
      using infusion clearance technique of para-aminohippuric acid and Chromium
      ethylenediaminetetraacetic acid (Cr-EDTA) respectively.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal blood flow</measure>
    <time_frame>5 Hours</time_frame>
    <description>Renal blood flow will be measured using infusion clearance technique of para-aminohippuric acid. Measurements will be made in duplicates before and after administration of the study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>5 Hours</time_frame>
    <description>Filtration fraction will be determined using be measured using infusion clearance technique of Chromium ethylenediaminetetraacetic acid (Cr-EDTA). Measurements will be made in duplicates before and after administration of the study drug. Glomerular filtration rate will be calculated as the filtration fraction multiplied by renal plasma flow.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>4 days</time_frame>
    <description>Measurement of serum creatinine will be made daily the first 4 days after the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Renal Insufficiency, Acute</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <arm_group_label>Levosimendan</arm_group_label>
    <other_name>Simdax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sodium chloride</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in the cardiothoracic intensive care after cardiac surgery with
             cardiopulmonary bypass

          -  Acute kidney injury, defined as increase in S-creatinine 50% or 27 mol/L

          -  Normal S-creatinine before surgery

        Exclusion Criteria:

          -  Ongoing treatment with inotropic drugs (not norepinephrine)

          -  Central venous oxygen saturation (ScvO2) &lt; 60% despite optimization of hematocrit and
             volume status

          -  Need of renal replacement therapy

          -  Ongoing bleeding

          -  Patient or next of kin does not consent with study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Sahlgrenska Academy, dept of clinical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukas Lannemyr, M D</last_name>
    <phone>+46-31-3428860</phone>
    <email>lukas.lannemyr@vgregion.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven-Erik Ricksten, Professor</last_name>
    <email>sven-erik.ricksten@aniv.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of thoracic anesthesia, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Lannemyr, MD</last_name>
      <phone>+46-31-3428860</phone>
      <email>lukas.lannemyr@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Sven-Erik Ricksten, Professor</last_name>
      <email>sven-erik.ricksten@aniv.gu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bragadottir G, Redfors B, Ricksten SE. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013 Oct;41(10):2328-35. doi: 10.1097/CCM.0b013e31828e946a.</citation>
    <PMID>23921271</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Lukas Lannemyr</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>acute kidney injury</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>renal blood flow</keyword>
  <keyword>levosimendan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

